Shukra Pharmaceuticals Ltd

Shukra Pharmaceuticals Ltd announced its Un-Audited Financial Results for the First Quarter ended June 30, 2026. The company reported a Net Profit of ₹1,502.98 Lakhs for the quarter, a significant increase compared to the previous periods. Total Income from Operations stood at ₹2,406.20 Lakhs. The Board of Directors approved these results, which have been reviewed by the Audit Committee and audited by M/s Shah Sanghvi and Associates. The company also confirmed no investor complaints were received during the quarter.

Shukra Pharmaceuticals Ltd announced its un-audited financial results for the first quarter ended June 30, 2026. The Board of Directors approved these results along with the Auditors' Limited Review Report. The financial statements were reviewed by the Audit Committee and audited by M/s Shah Sanghvi and Associates. The company reported its standalone and consolidated financial results for the period. No investor complaints were received during the quarter.

Shukra Pharmaceuticals Ltd has announced a revision to its Board Meeting date. The meeting, originally scheduled for August 11, 2026, will now take place on August 12, 2026. The agenda includes the consideration and approval of the unaudited financial results for the quarter ended June 30, 2026, along with the Auditor's Limited Review Report. The meeting will be held at the company's registered office.

Shukra Pharmaceuticals Ltd has announced that its Board of Directors will convene on August 11, 2026. The primary agenda items include the consideration and approval of the unaudited financial results for the quarter ended June 30, 2026, along with the accompanying Auditor's Limited Review Report. The meeting will also address any other business as permitted by the Chairman. This announcement is made in compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Shukra Pharmaceuticals Limited announced that its Board of Directors, in a meeting held on July 14, 2026, confirmed the receipt of differential upfront consideration for 46,43,000 convertible equity warrants. The allottees paid an additional amount of Rs. 0.39 per warrant, totaling Rs. 18,10,770, to account for a re-computation of the issue price from Rs. 34.00 to Rs. 35.56 per warrant. This payment was made within the stipulated 15-day period from the special resolution date. Additionally, two allottees paid the remaining 75% of the differential upfront amount, aggregating to Rs. 20,29,950. These actions ensure full compliance with SEBI ICDR Regulations.

Shukra Pharmaceuticals Ltd held its Extra Ordinary General Meeting (EOGM) on July 06, 2026, via Video Conferencing. The sole resolution presented, concerning the preferential issue of 46,43,000 Convertible Equity Warrants to Promoters for cash consideration, was passed. The meeting was conducted in accordance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The results of the e-voting process, along with the Scrutinizer's Report dated July 06, 2026, have been submitted and will be available on the company's website. The resolution received unanimous approval from the voting shareholders.

Shukra Pharmaceuticals Ltd has announced the closure of its trading window for dealing in the company's securities. This closure is effective from July 1, 2026, and will remain in effect until 48 hours after the declaration of its Unaudited Financial Results for the Quarter ended June 30, 2026. The decision aligns with SEBI regulations and the company's Insider Trading Code, prohibiting transactions by promoters, directors, KMPs, insiders, and connected persons, including their immediate relatives. The specific date for the Board Meeting to approve these financial results will be announced later.

Shukra Pharmaceuticals Ltd has announced an Extra Ordinary General Meeting (EGM) to be held on July 6, 2026, via Video Conferencing. The primary agenda is to seek shareholder approval for a preferential issue of 46,43,000 Convertible Equity Warrants to promoters. This move is in accordance with SEBI (ICDR) Regulations, 2018, and other applicable laws. The meeting will also address other businesses as may be decided by the Board.

Shukra Pharmaceuticals Ltd's Board of Directors met on June 10, 2026, to approve seeking fresh shareholder approval for a preferential issue of 46,43,000 Convertible Equity Warrants. The original approval from November 1, 2025, lapsed due to timing issues. The issue price will be re-computed as per SEBI ICDR Regulations, not lower than ₹34 per warrant. The company will hold an EGM on July 6, 2026, to pass a special resolution. Ms. Rupal Patel has been appointed as Scrutinizer. The total issue size is approximately ₹16.51 crore at a revised price of ₹35.56 per warrant.

Shukra Pharmaceuticals Ltd has announced a Board of Directors meeting scheduled for June 10, 2026. The primary agenda item is to ratify a member's resolution from an Extra-Ordinary General Meeting held on November 1, 2025, concerning an allotment. This ratification is required by BSE as the allotment was not completed within 15 days of the in-principle approval received on January 9, 2026. The company also plans to approve a draft notice for a postal ballot to seek shareholder ratification for this allotment under SEBI (ICDR) Regulations.